• 호남수학학술지
• /
• 제36권3호
• /
• pp.623-635
• /
• 2014

Classications of (${\alpha},{\beta}$)-fuzzy subalgebras of BCK/BCI-algebras are discussed. Relations between (${\in},{\in}{\vee}q$)-fuzzy subalgebras and ($q,{\in}{\vee}q$)-fuzzy subalgebras are established. Given special sets, so called t-q-set and t-${\in}{\vee}q$-set, conditions for the t-q-set and t-${\in}{\vee}q$-set to be subalgebras are considered. The notions of $({\in},q)^{max}$-fuzzy subalgebra, $(q,{\in})^{max}$-fuzzy subalgebra and $(q,{\in}{\vee}q)^{max}$-fuzzy subalgebra are introduced. Conditions for a fuzzy set to be an $({\in},q)^{max}$-fuzzy subalgebra, a $(q,{\in})^{max}$-fuzzy subalgebra and a $(q,{\in}{\vee}q)^{max}$-fuzzy subalgebra are considered.

• 대한전자공학회논문지SD
• /
• 제37권3호
• /
• pp.20-26
• /
• 2000

본 연구에서는 온도의 증가에 따른 RF-CMOS의 ｇ/sub m/과 ｆ/sub T/ 및 f/sub max/의 감소를 측정하였다. RF응용에서 MOS소자는 포화영역에서 동작되므로 모든 측정바이어스에서 온도에 따른 g/sub m/특성 변화를 실험적인 관계식으로 모델링하였다. CMOS의 f/sub T/와f/sub max/는 g/sub m/에 비례하기 때문에 온도에 따른f/sub T/ 및 f/sub max/ 변화도 온도에 따른 g/sub m/관계식으로부터 구할 수 있었다. 그리고 온도 증가에 따른fт와f/sub max/ 감소는 대부분 g/sub m/ 감소에 기인되며 DC와 RF특성 상관관계로부터 저온에서는f/sub T/와f/sub max/가 크게 증가됨을 예견할 수 있었다.

• Journal of Pharmaceutical Investigation
• /
• 제32권1호
• /
• pp.47-54
• /
• 2002

Cimetropium bromide, a quaternary ammonium compound which is chemically related to scopolamine, exhibits its antispasmodic activity by competing with acetylcholine for the muscarinic receptors of the smooth muscle of gastrointestinal tract. The drug has been used for the treatment of various disorders involving spasms of the musculature of the gastrointestinal, biliary and genitourinary tracts. The purpose of the present study was to evaluate the bioequivalence of two cimetropium bromide tablets, $Algiron^{TM}$ (Boehringer Ingelheim Korea Ltd.) and $Alpit^{TM}$ (Hana Pharmaceutical Co., Ltd.), according to the prior and revised guidelines of Korea Food and Drug Administration (KFDA). The cimetropium bromide release from the two cimetropium bromide tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, $25.25{\pm}2.10$ years in age and $65.76{\pm}6.39$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three tablets containing 50 mg of cimetropium bromide per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of cimetropium bromide in serum were determined using HPLC method with UV detector. The dissolution profiles of two cimetropium bromide tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using non-transformed and logarithmically transformed $AUC_t\;and\;C_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two tablets based on the $Algiron^{TM}$ were 2.19%, -5.97% and 3.49%, respectively. Minimum detectable differences $({\Delta})\;at \;{\alpha}=0.05\;and\;1-{\beta}=0.8$ were less than 20% (e.g., 13.71 %, 19.05% and 15.11% for $AUC_t,\;C_{max}\;and\;T_{max}$, respectively). The powers $(1-{\beta})\;at\;{\alpha}=0.05,\;{\Delta}=0.2\;for\;AUC_t$, $C_{max}\;and\;T_{max}$ were 97.79%, 83.22% and 95.60%, respectively. The 90% confidence intervals were within ${\pm}20%$ (e.g., $-5.84{\sim}10.21,\;-17.11{\sim}5.18\;and\;-5.35{\sim}12.33\;for\;AUC_t,\;C_{max}\;and\;T_{max}$, respectively). There were no sequence effect between two tablets in logarithmically transformed $AUC_t\;and\;C_{max}$. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., $0.94{\sim}1.10\;and\;0.85{\sim}1.05\;for\;AUC_t\;and\;C_{max}$, respectively). Two parameters met the criteria of prior and revised KFDA guideline for bioequivalence, indicating that $Alpit^{TM}$ tablet is bioequivalent to $Algiron^{TM}$ tablet.

• 한국전자통신학회논문지
• /
• 제9권7호
• /
• pp.827-834
• /
• 2014

본 논문에서는 WLAN/WiMAX시스템에 적용 가능한 삼중대역을 갖는 U-모양 안테나를 설계 및 제작하였다. 제안된 안테나는 U-모양의 평면형 모노폴 설계를 기본으로 U-모양 내부의 T-모양의 스터브를 구성함으로서 삼중대역 특성을 갖도록 설계하였다. 얻어진 최적화된 수치를 사용하여 제안된 안테나를 제작하였다. 시뮬레이션 결과와 측정결과가 어느 정도 일치하고 있는 데이터를 얻었으며 -10dB 임피던스 대역폭을 기준으로 WLAN/WiMAX 대역을 동시에 만족하고 있음을 확인하였다. 그리고 WLAN/WiMAX 대역에서 이득과 방사패턴의 특성을 얻었다.

• 한국식품영양과학회지
• /
• 제24권3호
• /
• pp.384-388
• /
• 1995

어유는 고도불포화지방산 함량이 높아 산화가 쉽게 되므로 식품가공용이나 기능성식품으로 응용되기에는 많은 제약이 따른다. 이러한 문제를 해결하기 위하여 어유의 산화안정성을 예측할 수 있는 기본 모델을 다음과 같은 식을 이용하여 제시하였다. $dp/dt=k{\cdot}p(t){\cdot}[P_{max}\;-\;p(t)]$. 상기식을 적분하면, $p(t)=P_{max}/[1\;+\;[(P_{max}/P_{(0)})\;-\;-1]{\cdot}EXP(-K_p{\cdot}t)]$. 여기서 산화온도가 50, 60와 70 및 $80^{\circ}C$ 일 때, $K_p$는 각각 0.00535, 0.01345와 0.02516 및 0.04657였다. 상기식은 대부분 측정치와 잘 일치하였다. 또한 $K_p$를 아래와 같이 온도의 함수로 표현할 수 있었다. $K_p=(1/P_{max})EXP\;[1\;-\;(8148/T)+20.1]$. 여기서 T 절대온도($^{o}K$)이다.

• Biomolecules & Therapeutics
• /
• 제15권2호
• /
• pp.118-122
• /
• 2007

This study was performed to evaluate the bioequivalency between the Osmetone$^{TM}$ Tablet (Myeongmoon Pharm. Co., Ltd.) as a test formulation and the Relafen$^{TM}$ Tablet (Handok Pharm. Co., Ltd.) as a reference formulation. Twenty-four healthy male volunteers were administered the formulations by the randomized Latin square crossover design, and the plasma samples were determined by a high performance liquid chromatography (HPLC) with Ultra-Violet (UV) detector. AUC$_t$, C$_{max}$ and T$_{max}$ were obtained from the time-plasma concentration curves, and log-transformed AUC$_t$ and C$_{max}$ and log-untransformed T$_{max}$ values for two formulations were compared by statistical tests and analysis of variation. AUC$_t$ was determined to be 897.8${\pm}$431.1 ug.hr/ml for the reference formulation and 902.3${\pm}$408.4 ug.hr/ml for the test formulation. The mean values of C$_{max}$ for the reference and test formulations were 24.2${\pm}$8.9 and 24.0${\pm}$9.5 ug/ml, respectively. The AUC$_t$ and C$_{max}$ ratios of the reference Relafen$^{TM}$ Tablet to the test Osmetone$^{TM}$ Tablet were +5.01% and -0.83%, respectively, showing that the mean differences were satisfied the acceptance criteria within 20%. The results from analysis of variance for logtransformed AUC$_t$ and C$_{max}$ indicated that sequence effects between groups were not exerted and 90% confidence limits of the mean differences for AUC$_t$ and C$_{max}$ were located in ranges from log 0.80 to log 1.25, satisfying the acceptance criteria of the KFDA bioequivalence. The Osmetone$^{TM}$ Tablet as the test formulation was considered to be bioequivalant to the Relafen$^{TM}$ Tablet used as its reference formulation, based on AUC$_t$ and C$_{max}$ values.

• Biomolecules & Therapeutics
• /
• 제14권1호
• /
• pp.50-55
• /
• 2006

The objective of the study was to evaluate the bioequivalency between the $Rozid^{TM}$ Tablet (Ilhwa Pharm. Co., Ltd.) as a test formulation and the $Rulid^{TM}$ Tablet (Handok Pharm. Co., Ltd) as a reference formulation. Twenty-four healthy male volunteers were administered the formulations by the randomized Latin square crossover design, and the plasma samples were determined by a high performance liquid chromatography (HPLC) with fluorescence detector. $AUC_t,\;C_{max}\;and\;T_{max}$ were obtained from the time-plasma concentration curves, and log-transformed $AUC_t\;and\;C_{max}$ and log-untransformed $T_{max}$ values for two formulations were compared by statistical tests and analysis of variation. $AUC_t$ was determined to be $63.30{\pm}25.57{\mu}g.hr/ml$ for the test formulation and $64.02{\pm}29.27mg.hr/ml$ for the reference formulation. The mean values of $C_{max}$ for the test and reference formulations were $5.07{\pm}2.14\;and\;5.53{\pm}2.60{\mu}g/ml$, respectively. The $AUC_t,\;and\;C_{max}$ ratios of the test $Rozid^{TM}$ Tablet to the reference $Rulid^{TM}$ Tablet were -1.12% and -8.32%, respectively, showing that the mean differences were satisfied the acceptance criteria within 20%. The results from analysis of variance for log-transformed $AUC_t,\;and\;C_{max}$ indicated that sequence effects between groups were not exerted and 90% confidence limits of the mean differences for $AUC_t,\;and\;C_{max}$ were located in ranges from log 0.80 and log 1.25, satisfying the acceptance criteria of the KFDA bioequivalence. The RozidTM Tablet as the test formulation was considered to be bioequivalent to the RulidTM Tablet used as its reference formulation, based on $AUC_t,\;and\;C_{max}$ values.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.58-64
• /
• 2003

Ondansetron is a potent, highly selective 5-hydroxytryptamin $e_3$(5-H $T_3$) receptor-antagonist, for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiography, and the treatment of post-operative nausea and vomiting. The purpose of the present study was to evaluate the bioequivalence of two ondansetron tablets, Zofran (Glaxo Smithcline Korea Ltd.) and Onfran (Korea United Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 24.39$\pm$1.69 year in age and 69.00$\pm$6.74kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 8mg of ondansetron was orally administered, blood was taken at predetermined time intervals and the concentrations of ondansetron in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AVC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and T max between two tablets were 5.83％, 5.75％ and －5.71％, respectively when calculated against the Zofran, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were above 90％, above 90％ and below 60％, respectively. Minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 were less than 20％ (e.g., 12.74％ and 11.78％ for AUC and $C_{max}$ respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 34.22％). The 90％ confidence intervals were within $\pm$20％ (e.g., -2.73∼14.39 and -2.16∼13.67 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., -28.71∼17.28). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant difference in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., 5.83％ and 5.75％ for AUC and $C_{max}$ respectively). The 90％ confidence intervals for the log transformed data were the acceptance range of log 0.8 to log 1.25 (e.g., log 0.99∼log 1.15 and log 0.98∼log 1.15 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$, met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofrm1 tablet.t is bioequivalent to Zofrm1 tablet.m1 tablet.m1 tablet.m1 tablet.

• 한국안광학회지
• /
• 제6권2호
• /
• pp.59-63
• /
• 2001

대비 민감도를 측정할 대비 휘도는 두 편광 판의 회전과 spectrophotometer로 측정한 가시광 영역의 투과율 면적(T%nm)을 이용하였다. 2개의 contrast 값으로부터 contrast sensitivity(Cs) 계산은 평균 contrast, $L_{max}$ 및 ${\theta}_{max}$ 값을 일정하게 한 후 $L_{min}$ ${\theta}_{min}$값을 계산하여 얻었다. 실험결과 $L_{max}=4000(T%nm)$, ${\theta}_{max}=44.1^{\circ}$로 고정시키고, Cs값이 2.5 및 100에서 $L_{min}$값은 각각 1333, 2666 및 3920(T%nm)이고, ${\theta}_{min}$값은 각각 56.6, 54.3 및 $45^{\circ}$이다.

• 한국인터넷방송통신학회논문지
• /
• 제14권2호
• /
• pp.59-64
• /
• 2014

본 논문은 이동통신 네트워크에서 WiMAX 백홀 구현에 관한 것이다. 최근에 대부분의 ISP들은 T1/E1 및 디지털 가입자 회선(DSL)을 이용하여 Wi-Fi 백홀을 구축하고 있다. WiMAX가 이동통신 백홀의 대안으로 설치된다면, 설치 및 운용비가 대폭 절감될 것이다. 그리고 유선통신 인프라가 구축되어 있지 않은 서비스 지역을 커버하기 위한 비용 효율적인 솔류선중 하나가 될 것이다. WiMAX는 Base Station, Subscriber Station, 그리고 Relay에 사용될 수 있다. 본 논문에서 WiMAX 서버와 WiMAX SS를 구성하여 NAT 및 Port Forwarding 기능을 이용하여 상 하향에서 성능이 측정되었다.